Special Issue "Treatment of Refractory Glomerular Diseases: Challenges and Solutions"

A special issue of Medicina (ISSN 1648-9144). This special issue belongs to the section "Nephrology".

Deadline for manuscript submissions: 31 July 2023 | Viewed by 104

Special Issue Editor

Dr. Kouichi Hirayama
E-Mail Website
Guest Editor
Department of Nephrology, Tokyo Medical University, Inashiki, Ibaraki, Japan
Interests: glomerulonephritis; vasculitis; immunology

Special Issue Information

Dear Colleagues,

Glomerular diseases other than diabetic nephropathy account for approximately 25% of chronic kidney disease (CKD) patients worldwide. Given the long duration of glomerular disease and the complications and prognosis associated with underlying disease and treatment, it is critical to optimize management to control and prevent progressive kidney disease. Recently, the KDIGO 2021 clinical practice guidelines for the management of glomerular disease were published and are expected to improve the prognosis and complications of glomerular disease. However, the treatment of glomerular disease still primarily consists of corticosteroids with or without several immunosuppressants, and there are only a few established treatments for the molecules involved in onset and progression, such as biological agents.

This issue focuses on primary glomerular diseases (idiopathic nephrotic syndrome, membranous nephropathy, IgA nephropathy, etc.), secondary glomerular diseases other than diabetic nephropathy (IgA vasculitis, lupus nephritis, ANCA-associated vasculitis, etc.) and hereditary glomerular disorders (Alport syndrome, Fabry disease, etc.). This Special Issue also aims to accumulate knowledge about new treatments for these refractory glomerular diseases.

In this Special Issue, original research articles and reviews are both welcome. Research topics may include (but are not limited to) the following:

  1. Outcomes of and problems with gold-standard treatments;
  2. Potential novel therapeutic agents in animal models;
  3. Introducing new treatment options in case series or pilot studies;
  4. The discovery of new therapeutic biomarkers.

I look forward to receiving your contributions.

Dr. Kouichi Hirayama
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Medicina is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1800 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • idiopathic nephrotic syndrome
  • focal and segmental glomerulosclerosis
  • membranous nephropathy
  • membranoproliferative glomerulonephritis/C3 nephropathy
  • IgA nephropathy/vasculitis
  • lupus nephritis
  • ANCA-associated vasculitis
  • anti-GBM disease
  • hereditary glomerular diseases

Published Papers

This special issue is now open for submission.
Back to TopTop